Miningrecovery and dilution were calculated individually for each stope with dueconsideration given to the mining method.An economic NSR cut-off value (“COV”) of $35 per tonne was estimated based onhistorical and projected costs developed from first principles. Johann de Bono and colleagues delivered a poster presentation entitled “APhase I Study of the Combination of Intravenous Reolysin (REO) and Gemcitabine(GEM) in Patients (pts) with Advanced Cancer.” The results, which werepreviously announced in March 2009, demonstrated that the combination ofREOLYSIN and gemcitabine was well tolerated, and resulted in disease controlfor a majority of the patients. Oncolytics reported onMay 12, 2009, that full enrolment of 52 patients was completed, at which timenine patients were continuing on study.”The ASCO data are very encouraging, both in terms of efficacy in patientswith sarcoma, and in those with other tumor histologies in whom the IDD groupare investigating various REOLYSIN regimens,” said Dr. Monica Mita, the studyprincipal investigator at the Institute of Drug Development (IDD), the CancerTherapy and Research Center at the University of Texas Health Science Center,(UTHSC), San Antonio, Texas.The interim results demonstrate that the treatment has been well tolerated,with 15 of 36, or 42% of evaluable patients experiencing stable disease (SD)for more than 16 weeks, including five patients who have had SD for more than24 weeks One patient had SD for more than 80 weeks. The meeting is being held in Orlando, Florida from May 29 toJune 2, 2009.The presentation, entitled “A Phase II Study of Intravenous REOLYSIN(Wild-type Reovirus) in the Treatment of Patients with Bone and Soft TissueSarcomas Metastatic to the Lung” was delivered by Dr. (TSX: ONC,NASDAQ: ONCY) announced that interim results of a Phase II study ofintravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung werepresented May 30, 2009 at the American Society of Clinical Oncology (ASCO)annual meeting. Kanzer, CPA, JD Chairman and CEO Adeona Pharmaceuticals, Inc.
(734) 332-7800 x39Copyright 2009, Market Wire, All rights reserved.-0-. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II SarcomaTrial Results at ASCO Annual MeetingCALGARY, June 1 /PRNewswire-FirstCall/ – Oncolytics Biotech Inc. Adeona is at an early stage of development and may not everhave any products that generate significant revenue.
No forward-looking statements can beguaranteed and actual results may differ materially from such statements.The information in this release is provided only as of the date of thisrelease, and Adeona undertakes no obligation to update anyforward-looking statements contained in this release on account of newinformation, future events, or otherwise, except as required by law.Readers are urged to read to the Form 8-K and exhibits thereto associatedwith this press release and transaction and are urged to consider the riskthat Adeona may not elect to complete the acquisition of Hartlab asdescribed.For Further Information Contact: Steve H. Thesestatements are based upon current beliefs, expectations and assumptionsand are subject to a number of risks and uncertainties, many of which aredifficult to predict and include statements regarding designingadditional clinical trials for oral dnaJP1, Zinthionein, flupirtine, orTrimesta. In some casesforward-looking statements can be identified by terminology such as “may,”"should,” “potential,” “continue,” “expects,” “anticipates,” “intends,”"plans,” “believes,” “estimates,” and similar expressions. Since 2003, anincreasing body of research continues to implicate chronic copperexposure as a potential factor that may contribute to the progression ofdiseases of the mature population, especially Alzheimer’s disease.This release includes forward-looking statements on Adeona’s currentexpectations and projections about future events. By visiting ,users can view a brief informational video, review relevant literature,obtain a sensitive test card to test their tap water for copper and,should they wish to participate in HealthMine’s CopperProof National TapWater Survey, share their levels of copper in tap water andgeographically compare such levels to those of others.
HeathMine currently hosts twoWeb 2.0 websites, and the recently launched, a new informational website dedicated to increasingawareness of the potential health effects of chronic copper toxicity,especially in the mature population. Forfurther information, please visit HealthMine, Inc.HealthMine, Inc., a subsidiary of Adeona Pharmaceuticals Inc., is a healtheducation communication and information resource company dedicated toraising awareness of subclinical zinc deficiency and the risks of chroniccopper toxicity in the mature population. Adeona believes that such conditions maycontribute to the progression of debilitating degenerative diseases,including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer’sdisease (AD) and mild cognitive impairment (MCI) in susceptible persons.Adeona is also developing a number of late-stage clinical drug candidatesfor the treatment of rheumatoid arthritis and multiple sclerosis. (NYSE Amex: AEN) is a specialtypharmaceutical company dedicated to the awareness, diagnosis, preventionand treatment of subclinical zinc deficiency and chronic copper toxicityin the mature population. Adeona intends tomaintain the operations and employees of Hartlab and is also requiringthat the current owner/founder enter into a consulting agreement toassist in the transition and operation of the company for a period oftime.About Adeona Pharmaceuticals, Inc.Adeona Pharmaceuticals, Inc. Adeona haspaid a non-refundable deposit of $14,000 and will pay an additional$266,000 at closing on or before June 30, 2009 in exchange for all of theissued and outstanding membership interests of Hartlab. Results from the study also indicatethat it may be useful to screen the existing Parkinson’s diseasepopulation for signs of Wilson’s disease, an effort that Adeona hopes topromote and accomplish through Hartlab.